NASDAQ · PROC
Procaps Group S.A.
$1.01+$1.01 (+100.0%)
Procaps Group S.A.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
Loading market information…
NASDAQ · CUTR · USD
Stock price, earnings
Quote as of Mar 12, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cutera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cutera, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cutera, Inc. is a medical technology enterprise specializing in the research, development, manufacturing, marketing, and servicing of cutting-edge laser and energy-based aesthetic systems for medical professionals worldwide. The company's comprehensive product line includes several advanced devices: Secret PRO, an innovative system combining fractional CO2 technology for thorough skin resurfacing with radio frequency (RF) microneedling for deep dermal tissue restructuring. truSculpt flex, a bio-electrical muscle stimulation apparatus engineered to support individuals across all fitness capabilities. excel V+, a versatile platform designed for addressing vascular and benign pigmented lesions. truSculpt iD, specifically tailored for the non-invasive body contouring sector. Secret RF, a fractional RF microneedling system that promotes precise tissue coagulation and hemostasis. Cutera also provides robust multi-application platforms: The enlighten platform, a laser system highly effective for tattoo removal, as well as treating benign pigmented lesions and acne scarring. The excel HR platform, offering an extensive hair removal solution compatible with diverse skin types. The xeo platform, a adaptable system where users can acquire various handpiece attachments to manage unwanted hair, treat vascular lesions, and achieve overall skin revitalization by targeting discoloration, fine lines, and laxity. In addition to its device offerings, Cutera distributes a range of skincare products and delivers post-warranty support, accessible via extended service agreements or direct billing. The company supplies specialized pulsed light handpieces for treating discoloration, facilitating hair removal, and managing vascular conditions. It further offers Pearl and Pearl Fractional handpieces, along with essential consumables such as handpiece refills, cycle refills, consumable tips, and marketing materials, all available for purchase through its official website. Cutera's products are marketed and sold through a direct sales team, reaching a wide spectrum of medical and aesthetic professionals. This includes plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, other certified practitioners, and even medical doctors performing aesthetic procedures in non-clinical environments. Founded in 1988, Cutera, Inc. maintains its corporate headquarters in Brisbane, California.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 |
|---|
| Aug 8, 2023 |
| -$0.69-25.45% vs estimate |
| $61.22M-5.75% vs estimate |
| Q1 2023 | May 9, 2023 | -$0.80-166.67% vs estimate | $54.99M-8.04% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.01+$1.01 (+100.0%)
Procaps Group S.A.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
$1.73-$0.02 (-1.14%)
Vyome Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.63% below the high.
$0.85-$0.26 (-23.42%)
Fresh2 Group Limited’s quoted price sits in the lower half of its reported 52-week range, 90.56% below the high.
$0.17-$0.04 (-18.69%)
Sientra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$0.29-$0.06 (-18.5%)
Midatech Pharma plc’s quoted price sits in the lower half of its reported 52-week range, 98.63% below the high.
$0.07-$0.07 (-50.87%)
VBI Vaccines Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.16% below the high.
$0.42+$0.42 (+100.0%)
CareMax, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.94% below the high.
$2.20+$0.17 (+8.37%)
NAYA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.09% below the high.
